Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results and discussion
about
Ubiquitin-Synaptobrevin Fusion Protein Causes Degeneration of Presynaptic Motor Terminals in MiceEmerging Roles of Filopodia and Dendritic Spines in Motoneuron Plasticity during Development and DiseaseBrain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?INaP selective inhibition reverts precocious inter- and motorneurons hyperexcitability in the Sod1-G93R zebrafish ALS modelCopper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SODExploring new pathways of neurodegeneration in ALS: the role of mitochondria quality controlMonitoring peripheral nerve degeneration in ALS by label-free stimulated Raman scattering imaging.Experimental Design and Data Analysis Issues Contribute to Inconsistent Results of C-Bouton Changes in Amyotrophic Lateral Sclerosis.Deregulated expression of cytoskeleton related genes in the spinal cord and sciatic nerve of presymptomatic SOD1(G93A) Amyotrophic Lateral Sclerosis mouse model.Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis.The secreted MSP domain of C. elegans VAPB homolog VPR-1 patterns the adult striated muscle mitochondrial reticulum via SMN-1Abnormalities of Mitochondrial Dynamics in Neurodegenerative Diseases.Mitochondrial alarmins released by degenerating motor axon terminals activate perisynaptic Schwann cellsEarly-stage treatment with Withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis.Isolation and functional analysis of mitochondria from cultured cells and mouse tissueElevated mRNA-levels of distinct mitochondrial and plasma membrane Ca(2+) transporters in individual hypoglossal motor neurons of endstage SOD1 transgenic mice.Neuroprotective Effect of Bexarotene in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosisMeasuring Neuromuscular Junction Functionality in the SOD1(G93A) Animal Model of Amyotrophic Lateral Sclerosis.Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis.Comparison of Diffusion MRI Acquisition Protocols for the In Vivo Characterization of the Mouse Spinal Cord: Variability Analysis and Application to an Amyotrophic Lateral Sclerosis Model.Snake and Spider Toxins Induce a Rapid Recovery of Function of Botulinum Neurotoxin Paralysed Neuromuscular JunctionNeuregulin 1 confers neuroprotection in SOD1-linked amyotrophic lateral sclerosis mice via restoration of C-boutons of spinal motor neurons.Progressive impairment of CaV1.1 function in the skeletal muscle of mice expressing a mutant type 1 Cu/Zn superoxide dismutase (G93A) linked to amyotrophic lateral sclerosis.Altered cortical beta-band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis.Neuregulin 1-ErbB module in C-bouton synapses on somatic motor neurons: molecular compartmentation and response to peripheral nerve injury.GDE2 is essential for neuronal survival in the postnatal mammalian spinal cord.Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1G93A mouse model of ALS.Amyotrophic lateral sclerosis: a long preclinical period?Increased expression of microRNA-29a in ALS mice: functional analysis of its inhibition.FTD and ALS--translating mouse studies into clinical trials.Targeting mitochondrial metal dyshomeostasis for the treatment of neurodegeneration.Hematopoietic stem and progenitor cells as novel prognostic biomarkers of longevity in a murine model for amyotrophic lateral sclerosis.A transgenic mouse expressing CHMP2Bintron5 mutant in neurons develops histological and behavioural features of amyotrophic lateral sclerosis and frontotemporal dementia.Endplate denervation correlates with Nogo-A muscle expression in amyotrophic lateral sclerosis patients.A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model.Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model.Motor Areas Show Altered Dendritic Structure in an Amyotrophic Lateral Sclerosis Mouse Model.Clinical, pathological and functional characterization of riboflavin-responsive neuropathy.Unraveling the role of motoneuron autophagy in ALS.
P2860
Q26269823-29ABA9C8-8468-4FDC-BC26-3BBAB438C1FDQ26769059-9C47E8B0-0A69-46D2-86E5-7350D86564ABQ26799233-B0D69C32-FD36-4437-9ED0-A733D12762D4Q27321452-152B5A87-685C-4B3E-887D-3CE78AF6CC63Q28272734-552F87D9-13D5-4E28-ADC1-26BECDA8CEB2Q28391199-260BBB9A-F8A3-4A3B-8EDD-222AD6F57CD2Q30827515-3937B100-A1C8-40BC-8D06-F64DB220F2CEQ31155328-9C648FFD-8FAD-4653-B4E1-136D46BF64BEQ33659976-D79AC87B-B9D8-48A9-B0CE-DA23840D6959Q33665800-90A18DA4-D92D-4D7D-86B6-FF6EC30FCFEDQ33830454-75D823CA-45A7-4DF3-A2C7-903C82C22904Q33845021-FBE0CC4B-1521-4C7A-B283-463AE4C56C1BQ35062594-1FD5DEF5-E48E-4D80-991D-BEA1C5DAFCFDQ35064952-0A423EC0-4B4A-4B86-B215-7BC92DDDBAB6Q35460893-F9F0992D-4B35-46D1-9961-A86EB45CDFA2Q35469175-6AE57ABA-B229-4FC7-A9E7-34C0508C2D16Q35802822-6D4173CB-B2FF-46E4-8B6B-E2A84801D079Q35822554-26DF4373-0BC7-428E-A21D-FA2A0C696EEAQ35894603-733398EA-3869-483F-B5AE-2EC3492FB293Q35899260-89A72353-DD1B-4D4A-BE63-029E2E3E6A3EQ36112950-2F91789C-3CC6-4B36-A764-7B2AE07F0E59Q36401493-AA1C0E6A-CDB5-4D48-905C-6F80E98DB47EQ36592116-6B11F3AB-BB2F-4651-B711-2FEC5DD84717Q37031363-29907A6D-FB45-4411-809A-4327BB8FAD28Q37561488-C70E435C-F895-47C9-A950-60BC6CE94C9DQ37571037-CD7A7E28-16CE-4ACD-8712-CC56153CAFEAQ37593544-B6A22067-A1B7-4CA9-B382-13C1ACE0B3BAQ37704485-20E56625-E164-4C53-BA2D-A7E07AB6952AQ38197553-898E5201-7AE2-42DF-9A50-A03235E230BCQ38308016-50F90556-4FEA-41E3-BEE7-6C1C32E88396Q38457811-B29EB378-43A9-4B57-8DCE-75D76A2806DAQ38570991-10C2ABFD-E197-4ECE-97C6-F766D8D26AC0Q38816820-16A9A18B-6E04-48B7-B2A9-38D5B8D0CDAEQ39665668-FCB117D1-F1BD-4D3F-8F01-6B047B456165Q39760999-2F9B94B0-A687-4C6E-B654-F3B20B30A917Q40140649-9BCC2C00-30F0-409D-9772-5F66F7FD80CDQ42749841-E1FD4057-B4F0-46A1-847E-712FC5C570AAQ47118168-06EC74AA-A2C5-4936-B4FE-E34C61245FFEQ47623812-E33305D4-4D5B-4F75-8988-3EDD4857FA0FQ47826863-515612B1-39DA-4574-977A-44B650FCE4FA
P2860
Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results and discussion
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characterization of early path ...... art II, results and discussion
@en
Characterization of early path ...... rt II, results and discussion.
@nl
type
label
Characterization of early path ...... art II, results and discussion
@en
Characterization of early path ...... rt II, results and discussion.
@nl
prefLabel
Characterization of early path ...... art II, results and discussion
@en
Characterization of early path ...... rt II, results and discussion.
@nl
P2093
P2860
P356
P1433
P1476
Characterization of early path ...... art II, results and discussion
@en
P2093
Carol Mansfield
Carol Milligan
David Prevette
Ramon Jimenez-Moreno
Ronald W Oppenheim
Sharon Vinsant
Thomas G Hampton
Victoria Del Gaizo Moore
P2860
P304
P356
10.1002/BRB3.142
P577
2013-06-11T00:00:00Z